Clinical Trials Arena December 6, 2024
Norwest Venture Partners, Sanofi Ventures, and Blue Owl Healthcare Opportunities co-led the financing.
Nuvig Therapeutics has closed a $161m Series B financing round to advance its preclinical pipeline and support NVG-2089’s clinical proof-of-concept trials.
The first-in-class recombinant Fc fragment immunomodulator, NVG-2089, is advancing into Phase II trial development, targeting chronic inflammatory demyelinating polyneuropathy (CIDP) and other conditions with significant treatment gaps.
A neurological autoimmune disorder, CIDP causes progressive weakness and sensory dysfunction in the limbs. Individuals with this condition often struggle with walking and climbing stairs.
Norwest Venture Partners, Sanofi Ventures, and Blue Owl Healthcare Opportunities co-led the financing.
New investors included Leaps by Bayer, B Capital, Global BioAccess Fund, Alexandria Venture Investments, Lotte Holdings, and funds managed by Abrdn.
...Today's Sponsors
Today's Sponsor